PL3712150T3 - Związek makrocykliczny służący jako inhibitor wee1 i jego zastosowania - Google Patents
Związek makrocykliczny służący jako inhibitor wee1 i jego zastosowaniaInfo
- Publication number
- PL3712150T3 PL3712150T3 PL18874492.4T PL18874492T PL3712150T3 PL 3712150 T3 PL3712150 T3 PL 3712150T3 PL 18874492 T PL18874492 T PL 18874492T PL 3712150 T3 PL3712150 T3 PL 3712150T3
- Authority
- PL
- Poland
- Prior art keywords
- applications
- macrocyclic compound
- compound serving
- wee1 inhibitor
- wee1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711058653 | 2017-11-01 | ||
| PCT/CN2018/112909 WO2019085933A1 (zh) | 2017-11-01 | 2018-10-31 | 作为Wee1抑制剂的大环类化合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3712150T3 true PL3712150T3 (pl) | 2024-09-02 |
Family
ID=66332843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18874492.4T PL3712150T3 (pl) | 2017-11-01 | 2018-10-31 | Związek makrocykliczny służący jako inhibitor wee1 i jego zastosowania |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11613545B2 (pl) |
| EP (1) | EP3712150B1 (pl) |
| JP (1) | JP7290638B2 (pl) |
| CN (2) | CN117534673A (pl) |
| AU (1) | AU2018361010B2 (pl) |
| BR (1) | BR112020008664A8 (pl) |
| CA (1) | CA3080842A1 (pl) |
| DK (1) | DK3712150T3 (pl) |
| ES (1) | ES2988855T3 (pl) |
| FI (1) | FI3712150T3 (pl) |
| HR (1) | HRP20241020T1 (pl) |
| HU (1) | HUE067795T2 (pl) |
| IL (1) | IL274357B2 (pl) |
| LT (1) | LT3712150T (pl) |
| PL (1) | PL3712150T3 (pl) |
| PT (1) | PT3712150T (pl) |
| RS (1) | RS65901B1 (pl) |
| SG (1) | SG11202003974XA (pl) |
| SI (1) | SI3712150T1 (pl) |
| SM (1) | SMT202400319T1 (pl) |
| WO (1) | WO2019085933A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604306B1 (en) * | 2017-03-23 | 2022-10-26 | Shanghai de Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
| EP3875460A4 (en) * | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
| HUE068061T2 (hu) * | 2019-04-30 | 2024-12-28 | Wuxi Biocity Biopharmaceutics Co Ltd | WEE1 inhibitor vegyület kristályos formája és felhasználása |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| JP2023508331A (ja) * | 2019-12-20 | 2023-03-02 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 組み合わせ |
| KR20220119428A (ko) * | 2019-12-20 | 2022-08-29 | 리커리엄 아이피 홀딩스, 엘엘씨 | 복합제 |
| CN115197221B (zh) * | 2021-04-02 | 2024-05-24 | 轩竹(北京)医药科技有限公司 | 二氢吡唑并嘧啶酮类大环衍生物及其用途 |
| CN115838375A (zh) * | 2021-09-18 | 2023-03-24 | 优领医药科技(香港)有限公司 | 含嘧啶并二氢吡唑啉酮类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023155892A1 (en) * | 2022-02-18 | 2023-08-24 | Insilico Medicine Ip Limited | Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| EP2155752B1 (en) | 2007-04-25 | 2018-09-19 | Merck Sharp & Dohme Corp. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| JPWO2009054332A1 (ja) * | 2007-10-23 | 2011-03-03 | 萬有製薬株式会社 | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| WO2010067886A1 (en) | 2008-12-12 | 2010-06-17 | Banyu Pharmaceutical Co.,Ltd. | Dihydropyrimidopyrimidine derivative |
| ES2524161T3 (es) | 2009-09-15 | 2014-12-04 | Merck Sharp & Dohme Corp. | Preparación de formas hemihidratadas cristalinas de dihidropirazolopirimidinona |
| US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| JP2014520855A (ja) | 2011-07-15 | 2014-08-25 | アッヴィ・インコーポレイテッド | 増殖性疾患の治療に有用な三環式キナーゼ阻害薬 |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| CN104011049A (zh) | 2011-10-20 | 2014-08-27 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| EP2817308B1 (en) | 2012-02-23 | 2016-09-07 | AbbVie Inc. | Pyridopyrimidinone inhibitors of kinases |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP3004096A1 (en) | 2013-06-06 | 2016-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2016344040B2 (en) | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| EP3604306B1 (en) | 2017-03-23 | 2022-10-26 | Shanghai de Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
| EP3875460A4 (en) * | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
-
2018
- 2018-10-31 AU AU2018361010A patent/AU2018361010B2/en active Active
- 2018-10-31 RS RS20240911A patent/RS65901B1/sr unknown
- 2018-10-31 US US16/759,769 patent/US11613545B2/en active Active
- 2018-10-31 HR HRP20241020TT patent/HRP20241020T1/hr unknown
- 2018-10-31 CN CN202311487748.4A patent/CN117534673A/zh active Pending
- 2018-10-31 HU HUE18874492A patent/HUE067795T2/hu unknown
- 2018-10-31 JP JP2020524447A patent/JP7290638B2/ja active Active
- 2018-10-31 LT LTEPPCT/CN2018/112909T patent/LT3712150T/lt unknown
- 2018-10-31 SM SM20240319T patent/SMT202400319T1/it unknown
- 2018-10-31 ES ES18874492T patent/ES2988855T3/es active Active
- 2018-10-31 WO PCT/CN2018/112909 patent/WO2019085933A1/zh not_active Ceased
- 2018-10-31 DK DK18874492.4T patent/DK3712150T3/da active
- 2018-10-31 EP EP18874492.4A patent/EP3712150B1/en active Active
- 2018-10-31 PL PL18874492.4T patent/PL3712150T3/pl unknown
- 2018-10-31 CN CN201880071103.3A patent/CN111344290B/zh active Active
- 2018-10-31 CA CA3080842A patent/CA3080842A1/en active Pending
- 2018-10-31 PT PT188744924T patent/PT3712150T/pt unknown
- 2018-10-31 BR BR112020008664A patent/BR112020008664A8/pt active IP Right Grant
- 2018-10-31 SG SG11202003974XA patent/SG11202003974XA/en unknown
- 2018-10-31 FI FIEP18874492.4T patent/FI3712150T3/fi active
- 2018-10-31 SI SI201831134T patent/SI3712150T1/sl unknown
-
2020
- 2020-04-30 IL IL274357A patent/IL274357B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3712150T (pt) | 2024-08-22 |
| AU2018361010A1 (en) | 2020-06-11 |
| LT3712150T (lt) | 2024-08-12 |
| FI3712150T3 (fi) | 2024-07-31 |
| BR112020008664A8 (pt) | 2023-01-17 |
| BR112020008664A2 (pt) | 2020-10-27 |
| US20200325145A1 (en) | 2020-10-15 |
| SI3712150T1 (sl) | 2024-09-30 |
| CN111344290B (zh) | 2023-12-01 |
| JP2021501191A (ja) | 2021-01-14 |
| HUE067795T2 (hu) | 2024-11-28 |
| IL274357B2 (en) | 2023-05-01 |
| HRP20241020T1 (hr) | 2024-11-08 |
| RU2020117443A3 (pl) | 2021-12-01 |
| EP3712150A1 (en) | 2020-09-23 |
| EP3712150B1 (en) | 2024-06-12 |
| DK3712150T3 (da) | 2024-07-29 |
| SMT202400319T1 (it) | 2024-09-16 |
| SG11202003974XA (en) | 2020-05-28 |
| EP3712150A4 (en) | 2021-03-10 |
| WO2019085933A1 (zh) | 2019-05-09 |
| RU2020117443A (ru) | 2021-12-01 |
| CN111344290A (zh) | 2020-06-26 |
| NZ764613A (en) | 2025-02-28 |
| US11613545B2 (en) | 2023-03-28 |
| ES2988855T3 (es) | 2024-11-21 |
| IL274357B1 (en) | 2023-01-01 |
| IL274357A (en) | 2020-06-30 |
| AU2018361010B2 (en) | 2023-01-12 |
| CA3080842A1 (en) | 2019-05-09 |
| RS65901B1 (sr) | 2024-09-30 |
| CN117534673A (zh) | 2024-02-09 |
| JP7290638B2 (ja) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274357A (en) | A macrocyclic compound used as a WEE1 inhibitor and its applications | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL269711B (en) | ask1 inhibitory compounds and uses thereof | |
| GB201708652D0 (en) | Novel compounds and uses | |
| EP3313449A4 (en) | Ionizable compounds and compositions and uses thereof | |
| IL264446A (en) | Compounds and compositions and their use | |
| GB201714734D0 (en) | New compounds and uses | |
| IL288991A (en) | A macrocyclic compound and its uses | |
| ZA201906135B (en) | Tri-cycle compound and applications thereof | |
| EP3268368A4 (en) | Aza-pyridone compounds and uses thereof | |
| SG10202100751YA (en) | Compounds and compositions and uses thereof | |
| GB201712110D0 (en) | New compounds and uses | |
| EP3247357A4 (en) | Isoergoline compounds and uses thereof | |
| EP3558993A4 (en) | AZAINDENOISOQUINOLINE COMPOUNDS AND USES THEREOF | |
| HK40023320A (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| HK40030347A (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| HK40008723A (en) | Compounds and compositions and uses thereof | |
| HK40013371A (en) | Compounds and uses thereof | |
| HK1240231A1 (en) | Benzoxaborole compounds and uses thereof |